还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
& `* {6 h! O3 h" h) |

1 ?! M" p2 j- m3 F& U! F# PSub-category:
) B& \+ c' ^3 o# zMolecular Targets


Category:
2 f9 n+ Y% M0 M; eTumor Biology
* Y* Q/ S; v3 O8 n+ D
: U# q8 P3 L( `8 a9 J
Meeting:
6 h, ~; C, j& u2011 ASCO Annual Meeting
. N+ G0 \# C' \' b* u8 U: |
( K' t" ]" }% e" F, z' j* ^
Session Type and Session Title:
Poster Discussion Session, Tumor Biology
5 d  D8 [  {# {1 a2 c

& g* c9 [- l0 a( bAbstract No:
10517
; C8 @* O5 ]' G1 a) e8 _, ~
9 |$ h, F' i1 x( i
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)


5 k  W$ ?/ r( ~( ]Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: O& A# S4 z. q+ ?8 K0 S5 U8 g* K
, Z. }' T4 s1 C9 \/ N0 L! G- X

, j; ]# O% p" s4 sAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

1 o5 L& R; L) x/ u+ a+ bAbstract Disclosures

7 k4 [# _$ w6 @Abstract:


Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 A! U" n) |% x1 N

3 t6 R; C- K! B2 A

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

; }$ |% B" C# P" u' F                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

5 n. `5 o7 u" I$ J! |易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
) X" c6 _, X$ q( H6 t+ S  |, VALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

. @# b+ x) m$ E; n$ Z1 a" `$ D现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊